Frontlight ResearchEarly access
Colorectal cancer trials in China
525 of 616 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Beijing, Jinan, Shanghai, Suzhou
- Age
- 18 years and over
- People
- 623 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - Phase 1/2Taking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- Age
- 18 years and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - Phase 1/2Taking peopleA Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Shanghai, Taizhou, Wuhan
- Age
- 18 years to 75 years
- People
- 570 worldwide
- Run by
- Tyligand Pharmaceuticals (Suzhou) Limited
See details and how to joinNCT06385925 - Phase 1/2Taking peopleA Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 450
- Run by
- Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT07198321 - No phaseTaking peopleThe Value of Early Postoperative Colonoscopy in The Early Diagnosis of Anastomotic Leakage After Surgery for Low Colorectal Cancer
- Where
- Nanchong
- Age
- 18 years to 80 years
- People
- 140
- Run by
- Nanchong Central Hospital
See details and how to joinNCT07588386 - Phase 2Taking peopleA Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
- Where
- Beijing, Bengbu, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Vividion Therapeutics, Inc.
See details and how to joinNCT07811193 · EU 2026-525507-26-00 - Phase 1/2Taking peopleSumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
- Where
- Beijing
- Age
- 18 years and over
- People
- 208 worldwide
- Run by
- Full-Life Technologies UK Limited
See details and how to joinNCT07873450 - Phase 2Not yet taking people in ChinaHLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
- Where
- Wuhan
- Age
- 18 years and over
- People
- 128
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07938021 - Phase 2Taking peopleA Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 25
- Run by
- Tao Zhang
See details and how to joinNCT07239466 - No phaseNot yet taking people in ChinaOral B-Complex Vitamin (B6, B9 and B12) Prevents Low Anterior Resection Syndrome in Rectal Cancer Patients With Hyperhomocysteinemia
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 134
- Run by
- Qilu Hospital of Shandong University
See details and how to joinNCT07928180 - Phase 2/3Taking peopleEfficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal Cancer
- Where
- Changchun
- Age
- 18 years to 75 years
- People
- 32
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07935759 - Phase 1Taking peopleA Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- Where
- Beijing, Guangzhou, Hangzhou
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Vividion Therapeutics, Inc.
See details and how to joinNCT06004245 · EU 2023-503170-20-01 - Phase 2Taking peopleTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 110
- Run by
- Teligene US
See details and how to joinNCT06589830 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Shenzhen, Taiyuan, Wanzhou, Wenzhou, Wuhan, Xiamen, Xi'an, Zhengzhou
- Age
- 18 years and over
- People
- 477 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06997497 · EU 2024-517232-22-00 - No phaseEnrolling by invitationAnesthetic Management Guided by the Medstrom Instrument
- Where
- Beijing
- Age
- 18 years to 65 years
- People
- 30
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07089017 - No phaseTaking peopleMulticenter Study of SIS Patch in High-risk Colorectal Anastomosis
- Where
- Beijing
- Age
- 18 years to 85 years
- People
- 255
- Run by
- Beijing Chao Yang Hospital
See details and how to joinNCT07931300 - Phase 2Active, not recruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Beijing, Hangzhou, Wuhan, Xi’an, Zhengzhou
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - Phase 2/3Enrolling by invitationEvaluating the Efficacy of Chidamide in the Treatment of Initial Unresectable Metastatic Colorectal Cancer With High Expression of SULF1
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 126
- Run by
- Sir Run Run Shaw Hospital
See details and how to joinNCT07927049 - Phase 2/3Enrolling by invitationEvaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 17
- Run by
- Sir Run Run Shaw Hospital
See details and how to joinNCT07927075 - Phase 3Taking peoplePhase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Where
- Beijing, Ch’ang-ch’un, Changsha, Chengdu, Chifeng, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Yueyang, Zhengzhou, Zhuhai
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT07228832 - Phase 3Taking peopleA Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Hong Kong, Meizhou, Nanchang, Nanjing, Nanning, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 1,020 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07549412 · EU 2025-524648-37-00 - No phaseNot yet taking people in ChinaRAPID for Unresectable Colorectal Liver Metastases
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 10
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07919951 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1Not yet taking people in ChinaA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Beijing, Tianjin
- Age
- 18 years and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - Phase 1Not yet taking people in ChinaA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00